Bristol Myers Squibb Company (NYSE:BMY – Free Report) – Equities researchers at Erste Group Bank raised their FY2027 earnings estimates for Bristol Myers Squibb in a report issued on Thursday, August 27th. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will earn $6.53 per share for the year, up from their previous estimate of $6.51. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.95 per share.
A number of other research analysts have also issued reports on BMY. Jefferies Financial Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, August 5th. JPMorgan Chase & Co. boosted their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Truist Financial restated a “buy” rating and issued a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Guggenheim reaffirmed a “buy” rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Piper Sandler assumed coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $66.06.
Bristol Myers Squibb Stock Performance
Shares of BMY stock opened at $66.72 on Monday. The firm has a market capitalization of $136.29 billion, a price-to-earnings ratio of 14.70, a PEG ratio of 0.32 and a beta of 0.23. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The business’s 50-day moving average price is $62.23 and its 200-day moving average price is $59.77. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $68.64.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the previous year, the company posted $1.46 EPS. Bristol Myers Squibb’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.
Institutional Investors Weigh In On Bristol Myers Squibb
Several large investors have recently modified their holdings of the company. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb during the 4th quarter worth about $25,000. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Davis Asset Management L.P. acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $27,000. Bayban bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at about $31,000. Finally, Addison Advisors LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth approximately $32,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.05% of the company’s stock.
Bristol Myers Squibb Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Articles
- Five stocks we like better than Bristol Myers Squibb
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
